Shares of Cleveland BioLabs Inc. (NASDAQ: CBLI), a biotechnology company engaged in the development of biodefense, tissue protection and cancer treatment drugs that are based on the concept of modulation of cell death for therapeutic benefit, are soaring today after the company reported strong survival results that met the primary endpoint of its Good Laboratory Practice (GLP) efficacy study.
At last check, CBLI shares were trading 62.20% higher at $2.06 on above average volume of 1.46 million.
The efficacy study of CBLB502 was conducted on 179 non-human primates (NHPs). The study was conducted under GLP with elements of Good Clinical Practice (GCP) as required by the FDA’s Animal Rule. The study results showed a high degree of statistical significance the dose-response relationship between the administration of CBLB502 and the survival of lethally irradiated animals.
Yakov Kogan, Ph. D., Interim CEO of Cleveland BioLabs, said that CBLB502 continues to exceed CBLI’s expectations.
Recent Comments